home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Cancer - Principles & Practice of Oncology
/
Oncology.iso
/
PPO
/
CHAP49
/
F3_2.CAP
< prev
next >
Wrap
Text File
|
1999-06-07
|
1KB
|
17 lines
FIGURE 49.3-2. Results from four randomized double-blind comparisons
of the major drugs used for acute treatment of cancer-related
hypercalcemia. Bars depict proportion of patients who achieved a
normal serum calcium value subsequent to treatment with the assigned
agent. All analyses are based on intent to treat. Numbers at bottom
indicate number of patients responding over number of patients treated
per group. The test drugs were administered on the following dose
schedules: (A) gallium nitrate, 200 mg/m**2, as a continuous IV
infusion daily for 5 days and etidronate, 7.5 mg/kg, as a 4-hour
infusion daily for 5 days [ref: 131]; (B) pamidronate, 60 mg, as a
single 24-hour infusion and etidronate, 7.5 mg/kg, as a 4-hour
infusion daily for 3 days [ref: 90]; (C) alendronate, 10 or 15 mg, as
a single 2-hour infusion and etidronate, 7.5 mg/kg, as a 4-hour
infusion daily for 3 days [ref: 103]; (D) gallium nitrate, 200
mg/m**2, as a continuous IV infusion daily for 5 days and pamidronate,
60 or 90 mg, as a single 24-hour infusion. [ref: 95]